Urban legends: pemphigus vulgaris
- Lookup NU author(s)
- Professor Marco Carrozzo
|
|
|
|
| Author(s) | | Cirillo N, Cozzani E, Carrozzo M, Grando SA |
| Publication type | | Article |
| Journal | | Oral Diseases |
| Year | | 2012 |
| Volume | | 18 |
| Issue | | 5 |
| Pages | | 442-458 |
| ISSN (print) | | 1354-523X |
| ISSN (electronic) | | 1601-0825 |
|
|
|
| Full text for this publication is not currently held within this repository. Alternative links are provided below where available. |
|
|
|
|
| Pemphigus vulgaris (PV) is the most common type of pemphigus. PV pathogenesis is still debated, and treatment remains challenging. We investigated five controversial topics: (1) What are the target antigens in PV? (2) Do desmogleins adequately address PV pathophysiology? (3) How does acantholysis occur in PV? (4) Is PV still a lethal disease? (5) What is the role of rituximab (RTX) in PV treatment? Results from extensive literature searches suggested the following: (1) Target antigens of PV include a variety of molecules and receptors that are not physically compartmentalized within the epidermis. (2) PV is caused by a variety of autoantibodies to keratinocyte self-antigens, which concur to cause blistering by acting synergistically. (3) The concept of apoptolysis distinguishes the unique mechanism of autoantibody-induced keratinocyte damage in PV from other known forms of cell death. (4) PV remains potentially life-threatening largely because of treatment side effects, but it is uncertain which therapies carry the highest likelihood of lethal risk. (5) RTX is a very promising treatment option in patients with widespread recalcitrant or life-threatening PV. RTX’s cost is an issue, its long-term side effects are still unknown, and randomized controlled trials are needed to establish the optimal dosing regimen. |
|
|
|
| Publisher | | Wiley-Blackwell Publishing, Inc. |
| URL | | http://dx.doi.org/10.1111/j.1601-0825.2011.01899.x |
| DOI | | 10.1111/j.1601-0825.2011.01899.x |
|
|
Actions | |   |
